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Distribution and Expression of Non-Neuronal
Transient Receptor Potential (TRPV)
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Mathias Sulk1,2, Stephan Seeliger3, Jerome Aubert4, Verena D. Schwab1, Ferda Cevikbas2, Michel Rivier4,
Pawel Nowak1, Johannes J. Voegel4, Jo¨rg Buddenkotte1,5 and Martin Steinhoff1,2,5
Rosacea is a frequent chronic inflammatory skin disease of unknown etiology. Because early rosacea reveals all
characteristics of neurogenic inflammation, a central role of sensory nerves in its pathophysiology has been
discussed. Neuroinflammatory mediators and their receptors involved in rosacea are poorly defined. Good
candidates may be transient receptor potential (TRP) ion channels of vanilloid type (TRPV), which can be
activated by many trigger factors of rosacea. Interestingly, TRPV2, TRPV3, and TRPV4 are expressed by both
neuronal and non-neuronal cells. Here, we analyzed the expression and distribution of TRPV receptors in the
various subtypes of rosacea on non-neuronal cells using immunohistochemistry, morphometry, double
immunoflourescence, and quantitative real-time PCR (qRT-PCR) as compared with healthy skin and lupus
erythematosus. Our results show that dermal immunolabeling of TRPV2 and TRPV3 and gene expression of
TRPV1 is significantly increased in erythematotelangiectatic rosacea (ETR). Papulopustular rosacea (PPR)
displayed an enhanced immunoreactivity for TRPV2, TRPV4, and also of TRPV2 gene expression. In phymatous
rosacea (PhR)-affected skin, dermal immunostaining of TRPV3 and TRPV4 and gene expression of TRPV1 and
TRPV3 was enhanced, whereas epidermal TRPV2 staining was decreased. Thus, dysregulation of TRPV channels
also expressed by non-neuronal cells may be critically involved in the initiation and/or development of rosacea.
TRP ion channels may be targets for the treatment of rosacea.
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INTRODUCTION
Rosacea is a common chronic skin disease of uncertain
etiology, which affects mainly the central facial region.
Because the pathophysiology of rosacea is still unclear, a
causal therapy is still poor (Powell, 2005; Steinhoff et al.,
2011; van Zuuren et al., 2011).
Rosacea can be categorized into four different subtypes
(Wilkin et al., 2002; Elewski et al., 2011). Subtype I,
erythematotelangiectatic rosacea (ETR), involves flushing—
often after trigger factors such as temperature changes, spicy
food, hot beverages, UV exposure, exercising, emotional
stress, or alcohol—facial erythema, and telangiectasia.
Subtype II, papulopustular rosacea (PPR), is associated
with papules and/or pustules in addition to erythema.
Subtype III, phymatous rosacea (PhR), is characterized by
skin fibrosis and glandular hyperplasia leading to phymata,
mainly rhinophyma. Another differentiated subtype is ocular
rosacea.
Etiopathological factors discussed are dysfunction of the
innate immune system, dermal matrix degeneration, chemi-
cal irritants, or microbial organisms (Yamasaki and Gallo,
2009; Zhang et al., 2011a). Because the symptoms of rosacea
such as vasodilation, flushing, increased skin sensitivity,
and lower pain thresholds (Guzman-Sanchez et al., 2007)
are caused by neuromediators (e.g., PACAP (pituitary
adenylate cyclase-activating polypeptide); Seeliger et al.,
2010), the involvement of the skin nervous system can be
anticipated. As classical neuronal receptors can also be
expressed by non-neuronal cells such as keratinocytes,
endothelial cells, and immune cells, a dysregulation of these
receptors on non-neuronal cells in rosacea has to be
considered as well.
TRPV (transient receptor potential vanilloid subfamily)
receptors are a subgroup of the heterogeneous TRP cation
channels with markedly diverse functions. The TRPV
subfamily consists of four nonselective cation channels
& 2012 The Society for Investigative Dermatology www.jidonline.org 1253
ORIGINAL ARTICLE
Received 9 June 2011; revised 12 October 2011; accepted 13 October 2011;
published online 22 December 2011
1Department of Dermatology, University Hospital Mu¨nster, Mu¨nster,
Germany; 2Departments of Dermatology and Surgery, University of California
San Francisco (UCSF), San Francisco, California, USA; 3Department of
Pediatric Cardiology, University of Go¨ttingen, Go¨ttingen, Germany and
4Galderma R&D, Sophia Antipolis, Biot, France
Correspondence: Martin Steinhoff, Departments of Dermatology and Surgery,
University of California San Francisco, 1701 Divisadero Street, San Francisco,
California 94115, USA. E-mail: steinhoffm@derm.ucsf.edu
5These authors contributed equally and shared senior authorship.
Abbreviations: ETR, erythematotelangiectatic rosacea; HS, healthy skin;
LE, lupus erythematosus; MC, mast cell; PPR, papulopustular rosacea; PhR,
phymatous rosacea; qRT-PCR, quantitative real-time PCR; TRPV, transient
receptor potential vanilloid subfamily
(TRPV1, TRPV2, TRPV3, and TRPV4) and two highly Ca2þ -
selective channels (TRPV5 and TRPV6; Nilius et al., 2007;
Aubdool and Brain, 2011).
TRPV1 is expressed on neuronal cells and has an important
role in nociception (Basbaum et al., 2009) and neurogenic
inflammation (Roosterman et al., 2006). In addition, in non-
neuronal cells, e.g., keratinocytes, TRPV1 is discussed to be
expressed (Pecze et al., 2008). It is activated by capsaicin
(‘‘spicy food’’), heat (442 1C), or under inflammatory condi-
tions. TRPV2 was found on neuropeptide-positive C-fibers and
many other non-neuronal cells, e.g., keratinocytes (Axelsson
et al., 2009) and macrophages (Link et al., 2010). It is
suggested to have a role in innate immunity, inflammation,
nociception, and sensing of noxious heat. TRPV3 is localized
on neuronal tissue, skin, and blood vessels (Earley et al.,
2010). TRPV3 is activated by innocuous warm temperatures
(32–39 1C) and is involved in thermosensation and keratino-
cyte differentiation (Cheng et al., 2010). TRPV4 is widely
spread on neuronal and non-neuronal cells, including
keratinocytes and endothelium. It is activated by moderate
heat (24–34 1C), hypotonic cell swelling, and inflammatory
metabolites. It may serve as an osmoreceptor, promote
vasodilation, and cause mechanical and inflammation-evoked
hyperalgesia (Vennekens et al., 2008).
According to the fact that TRPV channels can be activated
by typical trigger factors of rosacea, these receptors may have
a role in the pathophysiology of this disease by ‘‘sensing’’
exogenous and endogenous trigger factors in the skin.
Therefore, the aim of this study was to (1) investigate the
distribution of TRPV2, TRPV3, and TRPV4 in non-neuronal
cells of rosacea patients by immunohistochemistry and
double immunoflourescence, (2) perform a semiquantitative
analysis of the immunohistochemical data, (3) determine the
expression levels of TRPV1, TRPV2, TRPV3, and TRPV4 in
rosacea-affected skin by quantitative real-time PCR (qRT-
PCR), and (4) compare these results with skin tissues from
healthy donors and patients with lupus erythematosus (LE).
RESULTS
Dermal immunoreactivity of TRPV2 is enhanced in ETR and PPR
Immunohistochemical investigation of human skin revealed
immunoreactivity for TRPV2 in the epidermis of all study
groups (Figure 1a–e). Epidermal TRPV2 staining intensity
was rated semiquantitatively (Figure 1h) and showed a
decrease in PhR-affected skin (Po0.05), as compared with
healthy skin (HS). Thus, TRPV2 immunoreactivity was only
reduced in keratinocytes of PhR patients, and never increased
in any group.
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Figure 1. Localization of transient receptor potential vanilloid subfamily 2 (TRPV2) in erythematotelangiectatic rosacea (ETR), papulopustular rosacea
(PPR), phymatous rosacea (PhR), lupus erythematosus (LE), and healthy skin (HS), followed by semiquantitative analysis of TRPV2 immunoreactivity
in the epidermal or dermal compartment. (a–e) TRPV2 immunostaining was observed in keratinocytes in all study groups. (a, b, f) Strong dermal labeling
was found on immune cells in ETR and PPR. Fibroblasts and endothelial cells in (a) ETR, and smooth muscle cells of blood vessels in (g) PPR also showed
immunoreactivity. (h) Semiquantitative examination of epidermal TRPV2 staining displayed a decreased intensity in PhR (Po0.05) as compared with
HS. (i) Semiquantitative analysis of TRPV2-positive immune cells displayed an increased staining in PPR (Po0.01) and ETR (Po0.05) as compared with HS.
Additionally, PPR revealed an enhanced immunoreactivity and PPR as compared with LE (Po0.075). Bar¼ 100mm (a–f) and 50 mm (g); unfilled circles
represent outliers. *Po0.05, **Po0.01.
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Dermal staining for TRPV2 was observed in all investi-
gated groups. TRPV2 was localized on immune cells,
fibroblasts, and smooth muscle cells of blood vessels
(Figure 1g). Remarkably, multinucleated giant cells (Figure
1b), formed by the union of several macrophages,
showed marked immunoreactivity for TRPV2. Semiquantita-
tive scoring (Figure 1i) of positive dermal cells
showed increased staining in PPR (Po0.01), ETR (Po0.05),
and no statistical significance in LE or PhR, as compared with
HS. In addition, PPR revealed increased dermal immunor-
eactivity as compared with LE (Po0.075). Thus, TRPV2
immunoreactivity is enhanced in dermal cells of rosacea
patients.
TRPV2 is colocalized with CD68 and MC tryptase and is
upregulated in rosacea tissue
Double immunoflourescence reveals colocalization of
TRPV2 with CD68þ macrophages and mast cells (MCs) in
PPR (Figure 4a and b). In addition, immunolabeling for
TRPV2 in macrophages and MCs is enhanced in rosacea
tissue as compared with HS (Figure 4d and e). CD4þ T helper
cells show no convincing colocalization with TRPV2 in PPR
(Figure 4c).
Dermal immunostaining of TRPV3 is increased in ETR and PhR
Immunohistochemical staining of TRPV3 in human skin
showed positive staining for keratinocytes in all study groups
(Figure 2a–e). Semiquantitative scoring of epidermal TRPV3
staining intensity (Figure 2h) did not reveal any statistically
significant differences between skin affected by rosacea or LE,
as compared with HS. Thus, TRPV3 immunoreactivity can be
found in keratinocytes, but no differences were observed
between the study groups.
In the dermis, immunohistochemical data demonstrate
immunostaining for some fibroblasts and immune cells in
rosacea. Semiquantitative investigations (Figure 2i) of posi-
tive-stained dermal cells confirmed statistically significant
increased dermal staining in ETR (Po0.05) and PhR (Po0.01)
as compared with HS. Staining in PPR for TRPV3 was also
abundant (Po0.137), but did not reach statistical signifi-
cance. In sum, increased immunostaining for TRPV3 in
immune cells and fibroblasts was observed in rosacea as
compared with HS.
Dermal immunoreactivity of TRPV4 is enhanced in PPR and PhR
Immunohistochemical investigation of human skin revealed
TRPV4 labeling in the epidermis and dermis of all study
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Figure 2. Localization of transient receptor potential vanilloid subfamily 3 (TRPV3) in erythematotelangiectatic rosacea (ETR), papulopustular rosacea
(PPR), phymatous rosacea (PhR), lupus erythematosus (LE), and healthy skin (HS), followed by semiquantitative analysis of TRPV3 immunoreactivity
in the epidermal or dermal compartment. (a–e) TRPV3 immunostaining was observed in epidermal keratinocytes in all study groups. (a–g) Dermal labeling
was also evident in some immune cells, fibroblasts, and only reached intensity of background staining in endothelial cells and smooth muscle cells.
(h) Semiquantitative scoring of epidermal staining revealed a slight attenuated staining in ETR and PPR as compared with HS, but did not reach statistical
significance. (i) After semiquantitative examination of positive-stained dermal immune cells or fibroblasts, statistically significant increased scores were
found in ETR (*Po0.05) and PhR (**Po0.01) as compared with HS. Counterstaining with hematoxylin, Bar¼100 mm (a–g).
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groups (Figure 3a–f). Epidermal TRPV4 staining intensity was
rated semiquantitatively (Figure 3k) and displayed a tendency
for enhanced immunostaining in PhR, but semiquantitative
analysis did not show any statistically significant differences
between the study groups.
We also found dermal immune cells to be positive for
TRPV4 in rosacea-affected skin (Figure 3g and h), as compared
with LE or HS (Figure 3d–f), which showed no or very weak
immunostaining on dermal immune cells. In PPR, endothelial
cells, smooth muscle cells (Figure 3i), and Langerhans cells
(Figure 3j) showed immunolabeling for TRPV4. In sum,
semiquantitative examination (Figure 3l) revealed increased
staining for TRPV4 in immune cells of PPR (Po0.01) and PhR
(Po0.05), indicating an upregulation of TRPV4 in dermal
immune cells in comparison with HS and LE.
The role of neuronally expressed TRPV channels is part
of a different study using thick cryosections in order to
quantify TRPV-positive nerves in rosacea tissues (M Sulk,
J Buddenkotte, M Steinhoff, in preparation).
TRPV4 is colocalized with CD4, CD68, and MC tryptase in
rosacea tissue
Double immunoflourescence reveals colocalization of
TRPV4 with CD4þ T helper cells in PPR and interestingly
in PhR around a dilated blood vessel (Figure 4h and k).
CD68þ macrophages occasionally show colocalization with
TRPV4 in PPR and PhR (Figure 4f and i). Interestingly, MCs
show only colocalization with TRPV4 in PhR, whereas MCs
in PPR exhibit no colocalization (Figure 4j and g).
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Figure 3. Localization of transient receptor potential vanilloid subfamily 4 (TRPV4) in erythematotelangiectatic rosacea (ETR), papulopustular rosacea
(PPR), phymatous rosacea (PhR), lupus erythematosus (LE), and healthy skin (HS), followed by semiquantitative analysis of TRPV4 immunoreactivity
in the epidermal or dermal compartment. (a–f) TRPV4 immunostaining was located on keratinocytes in all study groups, on dermal immune cells of
rosacea, and in LE patients. Certain immune cells were strongly positive in (g) PPR and (h) PhR, whereas TRPV4-positive immune cells were only rarely
found in (e) LE. Interestingly, in PPR endothelial cells, (i) smooth muscle cells and (j) Langerhans cells showed immunolabeling. (k) Semiquantitative
analysis of epidermal staining revealed no significant differences. (l) Semiquantitative scoring of positive dermal cells confirmed an increased
staining for TRPV4 in PPR (Po0.01) and PhR (Po0.05) as compared with HS and LE. Bar¼ 100 mm (a–h) and 50 mm (i–j); unfilled circles
represent outliers. *Po0.05, **Po0.01.
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qRT-PCR reveals differential expression of TRPV1–4 genes in
rosacea
Expression levels of TRPV1–4 mRNA from skin biopsies of
rosacea and healthy patients were examined (Figure 5).
Our data demonstrate increased gene expression levels for
TRPV1 mRNA in all rosacea subtypes, especially in ETR and
PhR as compared with HS. Gene expression analysis for
TRPV2 mRNA showed a general decrease of Ct values,
indicating increased expression for all rosacea patients,
especially in PPR. Expression level for TRPV3 mRNA was
found to be enhanced in all rosacea subtypes, especially
in PhR. TRPV4 gene expression levels were diminished in
all rosacea subtypes, although without statistical significance
as compared with HS. In sum, TRPV1, TRPV2, and TRPV3
mRNA levels were found to be upregulated in rosacea,
although with differences among the various subtypes,
whereas TRPV4 mRNA levels were not changed in rosacea
patients.
DISCUSSION
In this study, we analyzed the distribution of TRPV2, TRPV3,
and TRPV4 receptors in non-neuronal cells of rosacea patients
as compared with HS and patients with LE. Semiquantitative
analysis of dermal and epidermal TRPV2, TRPV3, and TRPV4
immunolabeling revealed differences between skin of patients
suffering from rosacea and unaffected skin. Using qRT-PCR
technology, we showed a modulation of TRPV1, TRPV2,
TRPV3, and TRPV4 genes in rosacea patients (Supplementary
Table S1 online). The complex role of neuronal and non-
neuronal TRPV1 is part of a separate study (M Sulk,
J Buddenkotte, J Aubert et al., in preparation).
TRPV2
Semiquantitative immunohistochemical analysis of TRPV2
revealed decreased epidermal staining intensity in PhR and
increased immunoreactivity of dermal immune cells in all
investigated rosacea subtypes.
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Figure 4. Double immunofluorescence of transient receptor potential vanilloid subfamily 2 (TRPV2) and TRPV4 in patients with rosacea. TRPV2 reveals
colocalization with (a) CD68þ macrophages and (b) mast cell (MC) tryptase (Try) in papulopustular rosacea (PPR). (c) CD4þ T helper cells show no
convincing colocalization with TRPV2 in PPR (arrowheads). (d) In healthy skin (HS), macrophages showed only background staining for TRPV2 (arrowhead).
(e) Colocalization of TRPV2 in MCs in healthy skin was observed, and immunolabeling for TRPV2 in macrophages and MCs is enhanced in PPR as compared
with HS. TRPV4 shows colocalization with (f, i) CD68 (macrophages) and (h, k) CD4 (T helper cells). (g) No colocalization of TRPV4 with MC tryptase was
found in PPR (arrowhead), ( j) whereas TRPV4 shows colocalization with MCs surrounding a blood vessel in phymatous rosacea (PhR). Bar¼ 40 mm (g, h, j, k),
20mm (i), 15 mm (a–e, f), arrows indicate colocalization.
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Epidermal staining for TRPV2 was found previously
(Radtke et al., 2011) and a decrease in PhR might be based
on compensatory mechanisms due to UV radiation or
inflammation, but the role of TRPV2 on keratinocytes still
remains unclear.
Cardiac fibroblasts were described to express TRPV2
(Hatano et al., 2009). We also found immunoreactivity for
TRPV2 in some fibroblasts of rosacea patients, but the role of
TRPV2 on fibroblasts, myofibroblasts, and extracellular
matrix regulation needs further investigation.
Blood vessels also exhibited immunostaining for TRPV2 in
rosacea tissue, especially in smooth muscle cells. It is
noteworthy that TRPV2 activation has already been asso-
ciated with modulation of smooth muscle cell function in
other tissues related to vasodilation (Baylie and Brayden,
2011). The precise role of TRPV2 in cutaneous vasodilation
has to be determined in the future.
Previously, TRPV2 has been suggested to modulate
immune cell function. In particular, others found TRPV2 on
MCs (Kim et al., 2010), neutrophil granulocytes (Heiner et al.,
2003), lymphocytes (Saunders et al., 2007; Wenning et al.,
2011), and macrophages. Accordingly, macrophages and
MCs were shown to colocalize with TRPV2 and, in addition,
to be upregulated in PPR as compared with HS (Figure 4a, b,
d and e), which could explain the abundant immunolabeling
of TRPV2 in the dermal compartment of rosacea patients,
whereas CD4þ T helper cells revealed no colocalization
with TRPV2 in PPR. It is assumed that TRPV2 has an
important role in MC degranulation (Stokes et al., 2004;
Zhang et al., 2011b) and activation (Giudice et al., 2007),
whereas in neutrophils and lymphocytes its role remains
elusive. Recently, it was revealed that TRPV2 in macrophages
is essential for phagocytosis (Link et al., 2010), as well as
tumor necrosis factor-a and IL-6 production (Yamashiro et al.,
2010). TRPV2 expression was also shown in monocyte-
related cell types such as Langerhans cells (Shimohira et al.,
2009; Link et al., 2010) and phagocytic retinal pigment
epithelial cells where TRPV2 may regulate vascular endothe-
lial growth factor-A secretion (Cordeiro et al., 2010). The
precise characterization of TRPV2-expressing immune cells
in rosacea has to await further investigation.
According to our semiquantitative immunohistochemical
and double-immunoflourescence analysis, mRNA levels for
TRPV2 were also enhanced in all rosacea subtypes. In
particular, in PPR, expression rates were significantly
increased as compared with HS, which could be explained
by an increased number of TRPV2-expressing immune
cells, and an upregulation of TRPV2 mRNA in macrophages
and MCs may be due to inflammation (Shimosato et al.,
2005).
In sum, non-neuronal TRPV2 is expressed by various skin
and immune cells, and may be involved in vasoregulation
and immunomodulation, as described in mice (Link et al.,
2010). In rosacea, upregulated TRPV2 can be activated by
trigger factors (e.g., noxious heat), and thus could have a role
in the pathophysiology of rosacea.
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Figure 5. Normalized Ct values of individual genes (transient receptor potential vanilloid subfamily (TRPV)1–4) in healthy skin (HS) compared with
erythematotelangiectatic rosacea (ETR), papulopustular rosacea (PPR), and phymatous rosacea (PhR). The ends of the box indicate the lower and upper
25% quartiles. The line across the middle of the box identifies the median sample value. The width of the box is proportional to the number of observations.
The central line in each subfigure identifies the global mean. The P-values of the comparisons of gene expression levels in the different subtypes of rosacea
versus HS are indicated. In sum, TRPV1, TRPV2, and TRPV3 mRNA levels were found to be upregulated in rosacea, although with differences among the
various subtypes, whereas TRPV4 mRNA levels were not changed with statistical significance in rosacea patients. *Po0.05, **Po0.01.
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TRPV3
In rosacea-affected skin, increased immunostaining for
TRPV3 was observed in the dermal compartment, whereas
the epidermal compartment showed no differences, as
compared with HS. In addition, qRT-PCR revealed enhanced
TRPV3 gene expression levels in all rosacea subtypes.
Keratinocytes express functional TRPV3 and release IL-1a
(Xu et al., 2006), prostaglandin E2 (Huang et al., 2008),
transforming growth factor-a (Cheng et al., 2010), and nitric
oxide (Miyamoto et al., 2011) after TRPV3 activation. Thus,
TRPV3 on keratinocytes may modulate inflammation, fibro-
blast function, keratinocyte differentiation, vasodilation,
thermotransduction, and nociception. In addition, TRPV3
may be involved in the pathophysiology of atopic dermatitis
and elevation of MC numbers (Asakawa et al., 2006;
Yoshioka et al., 2009). As temperature changes and MCs
have an important role in rosacea pathophysiology (Aroni
et al., 2008; Schwab et al., 2011), one may speculate that
TRPV3 has a role in inflammatory and nociceptive processes
in rosacea, perhaps by regulating keratinocyte and MC
function.
Furthermore, some fibroblasts in PhR showed immunor-
eactivity for TRPV3. Accordingly, carvacrol, a well-known
TRPV3 agonist, induces type I collagen gene expression (Lee
et al., 2008). Thus, TRPV3 may also be involved in fibrotic
processes in rosacea.
Recent findings indicate a role of TRPV3 in regulating
lymphocyte function. In particular, B and T lymphocytes
were described to express TRPV3 (Inada et al., 2006;
Wenning et al., 2011). We also found increased immuno-
labeling of TRPV3 on dermal immune cells in all rosacea
subtypes. However, the precise role of TRPV3 as an
immunomodulator in inflammatory skin diseases and
the exact distribution of TRPV3 in specific dermal
immune cells in rosacea are still unknown and need further
exploration.
Blood vessels and especially endothelial cells were found
to express functional TRPV3 and mediate vasodilation (Earley
et al., 2010). However, we found only weak immunoreactiv-
ity of dermal endothelial cells in our study in rosacea tissue;
thus, a potential role of TRPV3 as a vasoregulator in rosacea
has to await further functional studies.
Upregulation of dermal TRPV3 and TRPV3 mRNA levels
may be associated with nociception (Gopinath et al., 2005;
Bang et al., 2011), tissue injury (Facer et al., 2007),
inflammation (Hu et al., 2006), and probably fibrosis. In
sum, non-neuronal TRPV3 is able to be activated by trigger
factors of rosacea, and thus could mediate and maintain
typical symptoms of rosacea.
TRPV4
In rosacea-affected skin, increased immunostaining for
TRPV4 was found in the dermal compartment, whereas the
epidermal compartment showed no differences as compared
with HS and also LE. In particular, PPR and PhR showed
enhanced immunostaining in dermal cells, whereas qRT-PCR
revealed no statistically significant changes with respect to
TRPV4 gene expression levels.
Recently, it was demonstrated that it is functionally
expressed in keratinocytes, and may contribute to barrier
integrity (Sokabe and Tominaga, 2010). According to recent
studies (Baylie and Brayden, 2011), also in rosacea endothe-
lial cells and smooth muscle cells showed TRPV4-immunor-
eactivity, and thus TRPV4 may mediate vasodilation in
rosacea patients. Furthermore, TRPV4 is assumed to have a
role in edema (Willette et al., 2008), angiogenesis due to
shear stress (Schierling et al., 2011), inflammation (Fiorio Pla
et al., 2011), and extracellular matrix deformation (Thodeti
et al., 2009).
In our study, increased localization of TRPV4 was also
found on dermal immune cells in rosacea-affected skin.
According to recent findings (Stokes et al., 2004; Kim et al.,
2010), we found that MCs express TRPV4, and a functional
role of TRPV4 in MC degranulation is suggested (Yang et al.,
2007).
In addition, TRPV4 has been described in macrophages
(Hamanaka et al., 2010) and lymphocytes (Inada et al., 2006;
Spinsanti et al., 2008; Wenning et al., 2011), which is
supported by our findings in rosacea patients (Figure 4). To
our knowledge, this is the first description of TRPV4 localized
on Langerhans cells. Thus far, a functional role of TRPV4 was
found for macrophage activation (Hamanaka et al., 2010)
However, a functional role of TRPV4 in skin immune cells
needs further investigation. Thus, increased dermal immuno-
staining in rosacea could be considered as MC, macrophage,
and/or CD4þ T helper cell related. Inflammation induced by
histamine (Cenac et al., 2010), proteases (Grant et al., 2007),
and prostaglandin E2 (Alessandri-Haber et al., 2003) may
lead to sensitization of TRPV4 on these cells and thus
modulate inflammatory processes, especially in patients with
rosacea.
As we found differences of TRPV4 expression on the
protein level but not on the RNA level, one may assume that
TRPV4 is regulated on the protein level rather than on the
transcriptional level in rosacea patients. Regulation of
(neuronal) TRPV4 on the translational level has been
described under inflammatory conditions (Cenac et al.,
2010; D’Aldebert et al., 2011; Fiorio Pla et al., 2011), which
may be due to desensitization and trafficking after repeated
stimulation (Guler et al., 2002). Another explanation could
be different sensitivities of immunohistochemistry and PCR,
respectively. We tried to determine the specificity on the
protein level by using two different primary antibodies
against TRPV2, TRPV3, and TRPV4, which all showed a
similar staining pattern (Supplementary Figure S1 online).
In sum, TRPV4 can be activated by rosacea trigger factors
and under inflammatory conditions. We found increased
immunostaining of TRPV4 in various dermal cells in rosacea
as compared with HS and—interestingly—LE. Therefore,
TRPV4 may be involved in inflammatory processes in
rosacea.
TRPV1 mRNA
The qRT-PCR analysis of TRPV1 expression of rosacea-
affected skin was performed, which revealed increased
TRPV1 mRNA expression levels in all rosacea subtypes when
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compared with HS, indicating a role of TRPV1 in rosacea.
Thus, the functional relevance of our qRT-PCR findings in
rosacea needs to be clarified. Because of its potential as a
future target in rosacea therapy (Steinhoff et al., 2011), the
role of TRPV1 protein and RNA in rosacea as compared with
other skin diseases with and without treatment is currently
under investigation (M Sulk, J Buddenkotte, J Aubert et al.,
in preparation).
In sum, non-neuronal TRPV channels are shown to be
differentially regulated and distributed among the various
rosacea subtypes. In ETR, dermal immunolabeling of TRPV2
and TRPV3 and also TRPV1 gene expression are significantly
increased. Clinically, ETR is characterized by flushing after
triggers such as temperature changes, spicy food, or UV/sun
exposure, and erythema. Histopathologically, an infiltrate of
lymphocytes and MCs was demonstrated (Marks and
Harcourt-Webster, 1969; Schwab et al., 2011). Flushing after
trigger factors could be mediated directly by TRPV2-positive
blood vessels or indirectly via activation and degranulation of
TRPV2-positive MCs. The precise role of TRPV2- and TRPV3-
positive lymphocytes and the increased TRPV1 gene expres-
sion in ETR has to be further investigated. The expression of
TRPV4 remained unchanged, although TRPV4 on blood
vessels and MCs might have a role in ETR. TRPV2 and TRPV3
immunostaining in ETR showed no significant changes as
compared with LE, which might be due to a similar
lymphocytic infiltrate in LE.
PPR displayed an enhanced dermal immunolabeling for
TRPV2, TRPV4, and also of TRPV2 gene expression.
Clinically, PPR is associated with papules and/or pustules in
addition to erythema. Histologically, an inflammatory infil-
trate of T cells, macrophages, MCs, and, occasionally,
neutrophils or B cells (Steinhoff et al., 2011) was described.
In PPR, inflammation could be mediated by macrophages
and MCs. TRPV2 and TRPV4 were found to be expressed by
these cells (Figure 4), whereas in the case of TRPV2 an
upregulation in rosacea tissue on macrophages was
demonstrated. As discussed above, a role of TRPV2 and
TRPV4 in mediating macrophage and MC functions is
assumed, and thus trigger factors of TRPV2 and TRPV4 could
initiate and maintain inflammation. The impact of TRPV4-
positive staining on CD4þ T helper cells in PPR needs
further investigation. In addition, mRNA of TRPV1 and
TRPV3 and also dermal immunolabeling for TRPV3 were
increased, which could be due to immunopositive lympho-
cytes. Interestingly, dermal immunostaining of TRPV2 and
TRPV4 in PPR was increased, as compared with LE. This
might indicate a specific role for TRPV2 and TRPV4 in PPR,
and the analysis of higher numbers of specimen may be
directive.
PhR shows an enhanced dermal immunostaining of
TRPV3 and TRPV4 and gene expression of TRPV1 and
TRPV3, whereas epidermal TRPV2 staining was decreased.
Clinically, PhR is characterized by skin fibrosis and glandular
hyperplasia. Histopathologically, vasodilation, angiogenesis,
fibrosis, edema and infiltration of MCs, lymphocytes,
plasmocytes, and macrophages were described (Aloi et al.,
2000; Schwab et al., 2011; Steinhoff et al., 2011). As noted
above, endothelial TRPV4 is assumed to mediate edema,
angiogenesis, inflammation, and extracellular matrix defor-
mation, which could all maintain or initiate symptoms of
PhR. In addition, TRPV4 on macrophages and MCs (Figure 4)
might modulate inflammatory and fibrotic processes via
macrophage activation and MC degranulation (Hermes et al.,
2001; Chujo et al., 2009). The role of TRPV4 and TRPV3 in
lymphocytes, as well as the upregulation of TRPV1 mRNA,
and the decreased staining of epidermal TRPV2 need further
investigations. Interestingly, dermal immunostaining of
TRPV4 in PhR was increased as compared with LE. This
might indicate a specific role for TRPV4 in PhR.
Clinically, LE patients can be characterized by a photo-
sensitive malar (butterfly) rash with erythematous macules or
infiltrated plaques with a tendency for confluence; histolo-
gically, a lymphocytic infiltrate is observed (Obermoser et al.,
2010). Dermal upregulation of TRPV2 and TRPV3 as
compared with HS could be explained by an enhanced
number of immunopositive lymphocytes. Despite this,
TRPV2–4 immunolabeling is increased in rosacea tissue as
compared with LE, which is caused by further immunoposi-
tive dermal cells such as MCs, macrophages, and blood
vessels.
In particular, in PPR, TRPV2 and TRPV4 and in PhR,
TRPV4 are upregulated as compared with LE, which might
indicate a specific role for TRPV2 and TRPV4 in rosacea.
In sum, non-neuronal TRPV1–4 cation channels are
differentially regulated in rosacea tissue and may thus have
an important role in the pathophysiology of this chronic
disease. After activation through typical rosacea trigger
factors (e.g., temperature changes, toxins, and spices), they
are able to mediate and maintain symptoms of rosacea,
such as inflammation, flushing, hypersensitive skin, MC
activation, and even fibrosis, and thus may be targets for
specific therapy. Nevertheless, further investigations are
necessary to reveal the precise function of TRPV-positive
non-neuronal cells in rosacea pathophysiology. In addition,
the functional relevance of TRPV channels in human
inflammatory skin diseases still needs to be clarified, and
the precise role of non-neuronal TRPV ion channels in
rosacea still remains unclear.
MATERIALS AND METHODS
Tissue collection
For (double) immunohistochemistry, 36 diagnostic skin biopsies
from patients with different subtypes of rosacea (ETR: n¼ 7; PPR:
n¼ 7, and PhR: n¼ 7), LE (n¼ 7), and HS (n¼ 8) were investigated.
The clinical diagnosis of rosacea subtypes was performed according
to the classification system of the National Rosacea Society (Wilkin
et al., 2002). For qRT-PCR, 40 patients were examined and skin from
healthy patients was obtained following plastic surgery (n¼ 12). Skin
biopsies of patients with rosacea subtype ETR (n¼ 11), PPR (n¼ 11),
and PhR (n¼ 6) were performed. Patients were informed about the
possible use of tissue leftover from surgery for investigation, and they
gave their written consent. Permission for human studies was given
by the Ethics Committee of the University of Mu¨nster, Germany, in
accordance with the ethical standards of the 1964 Declaration of
Helsinki Principles.
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Immunohistochemistry
Punch biopsies were embedded in paraffin and 7mm sections were
cut and mounted. Standard procedures were used as previously
described (Bocheva et al., 2009).
Tissues were incubated with antibodies for TRPV2, TRPV3, and
TRPV4 (Supplementary Table S2 online). As negative controls, the
primary antibodies were omitted (Supplementary Figure S1g–i
online). Pictures of the epidermis and dermis were taken from three
representative areas within each section. For specificity control, a
second primary antibody was used, which showed a similar staining
pattern (Supplementary Figure S1a–f online).
Semiquantitative image analysis
Epidermal intensity and the number and area of immunostained
dermal cells were rated on a scale of 0–4 (0¼ absent, 1¼weak/low,
2¼moderate, 3¼ strong, and 4¼ very strong staining).
Statistical analysis of immunohistochemistry
Statistical analysis was performed using SPSS (SPSS,
Chicago, IL). Statistical significance was determined using Student’s
t-test and differences were considered significant at a P-value of
o0.05.
Double immunoflourescence
For TRPV4, three rosacea tissues (PPR: n¼ 2, PhR: n¼ 1) and for
TRPV2 five PPR tissues and two HS samples were investigated
qualitatively. Costaining was performed together with antibodies
against CD4, CD68, and MC tryptase (Supplementary Table S1
online). As negative controls, preabsorption of antibodies at working
dilutions with an excess of the respective antigen (105 mol l–1,
48 hours before reaction) was performed.
RNA extraction and qRT-PCR
RNA extraction and qRT-PCR were performed as previously
described (Seeliger et al., 2010). In short, RNA was extracted,
quantity was measured, quality was monitored, and 800ng RNA was
used for synthesizing complementary DNA. Gene expression
analysis was performed using Ready-to-use TaqMan Gene Expres-
sion Assays (Applied Biosystems, Courtaboeuf, France; numbers are
listed in Supplementary Table S3 online). A triplicate determination
was performed for each sample. qRT-PCR was performed on
ABI7900HT (Applied Biosystems) with 50 ng synthesized comple-
mentary DNA. PCR threshold cycle (Ct) numbers were defined and
normalized Ct values were calculated. mRNA expression
was determined using the DCt method. Fold modulation of gene
expression of rosacea samples versus samples of HS was defined
as 2(mean CtHSmean CtRo), with CtHS and CtRo depicting the Ct values
of HS and rosacea samples, respectively.
Statistical analysis
To identify significantly modulated genes, one-way analysis of
variance with Benjamini–Hochberg multiplicity correction was
performed using JMP7.0.1 (SAS Institute, Cary, NC) and irMF3.5
(National Institute of Statistical Sciences (NISS), Research Triangle
Park, NC) software.
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